Issues
-
Cover Image
Cover Image
In this issue, Keisuke Kataoka and colleagues map the trajectory of adult T-cell leukemia/lymphoma (ATL) development driven by HTLV-1 infection in a large cohort of ATL patients, asymptomatic HTLV-1 carriers, and healthy controls. The study maps at single-cell resolution the cellular ecosystem populating the systemic immune landscape. It identifies biologically and clinically relevant cues to navigate this high-dimensional space, including phenotypic hallmark of premalignant clonal expansion. By tracking clonal evolution of the infected T cells toward malignancy, the authors reveal that the neoplastic transformation develops hand in hand with alterations in the noninfected lymphoid and myeloid compartments, including PD-L1 protein transfer from malignant T cells to their neighbors. For details, please see the article on page 450. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In This Issue
In The Spotlight
Reviews
Research Articles
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
A phase Ib trial of ficlatuzumab and cytarabine in high-risk AML reports a favorable safety profile and promising clinical activity. Multidimensional single-cell analyses collected before and after therapy identify several candidate prospective and pharmacodynamic biomarkers of response.
Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1
Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Mutation Signatures of Pediatric Acute Myeloid Leukemia and Normal Blood Progenitors Associated with Differential Patient Outcomes
ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.